- Indførelse af advarsler om neuroleptikas klassevirkninger (malignt neuroleptikasyndrom, QT - forlængelse, tardiv dyskinesi) og abstinenssymptomer som angst og depressivt syndrom.
-Introduction of warnings regarding class effects of neuroleptic medicines (neuroleptic malignant syndrome, QT prolongation, tardive dyskinesia) and withdrawal symptoms such as anxiety and depressive syndrome.